{
    "id": "56609346",
    "text": "Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases. This drug was developed by Gilead Sciences, Inc.Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association. Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019. == References == Category:Monoclonal antibodies ",
    "title": "Andecaliximab"
}